Form 8-K - Current report:
SEC Accession No. 0000950170-24-109377
Filing Date
2024-09-25
Accepted
2024-09-25 17:00:09
Documents
12
Period of Report
2024-09-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ktra-20240925.htm   iXBRL 8-K 68982
2 EX-2.1 ktra-ex2_1.htm EX-2.1 34803
  Complete submission text file 0000950170-24-109377.txt   231818

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ktra-20240925.xsd EX-101.SCH 27216
14 EXTRACTED XBRL INSTANCE DOCUMENT ktra-20240925_htm.xml XML 4909
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121 (858) 350-4364
Kintara Therapeutics, Inc. (Filer) CIK: 0001498382 (see all company filings)

EIN.: 990360497 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-37823 | Film No.: 241325331
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)